Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash ...

Surf Club opens Two and a half years ago, Allen Sanford told the Redondo Beach city council his plans for the first project ...

Qualcomm’s global commercial channel chief has left the chip designer, marking its second major channel departure as it ramps up competition against Intel and AMD.

Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline ...

Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...

With 2025 in the history books, the African aviation sector stands at a pivotal juncture, marked by ambitious infrastructure ...

Legacy load forecasting models are struggling with ever-more-common, unpredictable events; power-hungry AI offers a solution.

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

Here are 10 of the highest-paying dividend stocks you can buy right now, offering strong yields, reliable payouts, and ...

Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 ...

During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...